Synthesis and SAR study of novel peptide aldehydes as inhibitors of 20S proteasome

Molecules

Volumn 16, Issue 9, 2011, Pages 7551-7564

  Ma, Yuheng ^a   Xu, Bo ^a   Fang, Yuan ^a   Yang, Zhenjun ^a   Cui, Jingrong ^a   Zhang, Liangren ^a   Zhang, Lihe ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

20S proteasome; Inhibitor; Peptide aldehydes; Structure activity relationship; Synthesis

Indexed keywords

ALDEHYDE; OLIGOPEPTIDE; PROTEASOME; PROTEINASE INHIBITOR;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; ENZYME ASSAY; PROTEIN BINDING; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; SYNTHESIS;

ALDEHYDES; AMINO ACID MOTIFS; BINDING SITES; COMPUTER SIMULATION; ENZYME ASSAYS; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES;

EID: 80053248961     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16097551     Document Type: Article

References (43)

1. Etlinger, J.D.; Goldberg, A.L. Soluble Atp-dependent prooteolytic system resonsible for degradation of abnormal proteins in reticulocytes. Proc. Natl. Acad. Sci. USA 1977, 74, 54-58. (Pubitemid 8025869)
2. Hershko, A. Lessons from the discovery of the ubiquitin system. Trends Biochem. Sci. 1996, 21, 445-449. (Pubitemid 26393737)
3. Rock, K.L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A.L. Inhibitors of the proteasome block the degradation of most cell-proteins and the generation of peptides presented on Mhc Class-I molecules. Cell 1994, 78, 761-771. (Pubitemid 24294452)
4. Osaki, T.; Kimura, T.; Tatemoto, Y.; Lu, D.P.; Yoneda, K.; Yamamoto, T. Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. Oncology 2000, 59, 36-43. (Pubitemid 30435834)
5. Pagano, M.; Tam, S.W.; Theodoras, A.M.; Beerromero, P.; Delsal, G.; Chau, V.; Yew, P.R.; Draetta, G.F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269, 682-685.
6. Alves-Rodrigues, A.; Gregori, L.; Figueiredo-Pereira, M.E. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci. 1998, 21, 516-520. (Pubitemid 28555693)
7. Merforth, S.; Kuehn, L.; Osmers, A.; Dahmann, B. Alteration of 20S proteasome-subtypes and proteasome activator PA28 in skeletal muscle of rat after induction of diabetes mellitus. Int. J. Biochem. Cell Biol. 2003, 35, 740-748. (Pubitemid 36369521)
8. Sun, J.Z.; Nam, S.K.; Lee, C.S.; Li, B.Y.; Coppola, D.; Hamilton, A.D.; Dou, Q.P.; Sebti, S.M. CEP1612, a dipeptidyl proteasome inhibitor, induces p21(WAF1) and p27(KIP1) expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 2001, 61, 1280-1284. (Pubitemid 34292542)
9. Kisselev, A.F.; Goldberg, A.L. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 2001, 8, 739-758. (Pubitemid 32752454)
10. Groll, M.; Schellenberg, B.; Bachmann, A.S.; Archer, C.R.; Huber, R.; Powell, T.K.; Lindow, S.; Kaiser, M.; Dudler, R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008, 452, 755-758. (Pubitemid 351521080)
11. Pirrung, M.C.; Biswas, G.; Ibarra-Rivera, T.R. Total Synthesis of Syringolin A and B. Org. Lett. 2010, 12, 2402-2405.
12. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: Crystallographic knowledge for drug development. Chem. Rev. 2007, 107, 687-717. (Pubitemid 46502369)
13. Marques, A.J.; Palanimurugan, R.; Matias, A.C.; Ramos, P.C.; Dohmen, R.J. Catalytic mechanism and assembly of the proteasome. Chem. Rev. 2009, 109, 1509-1536.
14. Genin, E.; Reboud-Ravaux, M.; Vidal, J. Proteasome inhibitors: Recent advances and new perspectives in medicinal chemistry. Curr. Top. Med. Chem. 2010, 10, 232-256.
15. Arrigo, A.P.; Tanaka, K.; Goldberg, A.L.; Welch, W.J. Identity of the 19s prosome particle with the large multifunctional protease complex of mammalian-cells. Nature 1988, 331, 192-194. (Pubitemid 18042153)
16. Lowe, J.; Stock, D.; Jap, R.; Zwickl, P.; Baumeister, W.; Huber, R. Crystal-structure of the 20s proteasome from the archaeon T-acidophilum at 3.4-Angstrom resolution. Science 1995, 268, 533-539.
17. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H.D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 angstrom resolution. Nature 1997, 386, 463-471. (Pubitemid 27164066)
18. Unno, M.; Mizushima, T.; Morimoto, Y.; Tomisugi, Y.; Tanaka, K.; Yasuoka, N.; Tsukihara, T. The structure of the mammalian 20S proteasome at 2.75 angstrom resolution. Structure 2002, 10, 609-618. (Pubitemid 34518706)
19. Groll, M.; Larionov, O.V.; Huber, R.; de Meijere, A. Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation. Proc. Natl. Acad. Sci. USA 2006, 103, 4576-4579.
20. Kaiser, M.; Groll, M.; Siciliano, C.; Assfalg-Machleidt, I.; Weyher, E.; Kohno, J.; Milbradt, A.G.; Renner, C.; Huber, R.; Moroder, L. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. ChemBioChem 2004, 5, 1256-1266. (Pubitemid 39297256)
21. Groll, M.; Gotz, M.; Kaiser, M.; Weyher, E.; Moroder, L. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasom. Chem. Biol. 2006, 13, 607-614.
22. Clerc, J.; Florea, B.I.; Kraus, M.; Groll, M.; Huber, R.; Bachman, A.; Dudler, R.; Driessen, C.; Overkleeft, H.S.; Kaiser, M.C. Syringolin A selectively labels the 20S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. ChemBioChem 2009, 10, 2638-2643.
23. Groll, M.; Berkers, C.R.; Ploegh, H.L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006, 14, 451-456. (Pubitemid 43363478)
24. Meng, L.; Mohan, R.; Kwok, B.H.; Elofsson, M.; Sin, N.; Crews, C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. USA 1999, 96, 10403-10408. (Pubitemid 29422570)
25. Palmer, J.T.; Rasnick, D.; Klaus, J.L.; Bromme, D. Vinyl sulfones as mechanism-based cysteine protease inhbibitors. J. Med. Chem. 1995, 38, 3193-3196.
26. Omura, S.; Matsuzaki, K.; Fujimoto, T.; Kosuge, K.; Furuya, T.; Fujita, S.; Nakagawa, A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibiot. 1991, 44, 117-118.
27. Fenteany, G.; Standaert, R.F.; Lane, W.S.; Chois, S.; Corey, E.J.; Schreiber, S.L. Inhibition of proteasome activites and subunit-specific amino-terminal threonine modification by lactacystin. Scinece 1995, 268, 726-731.
28. Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew. Chem. Int. Ed. 2003, 42, 355-357. (Pubitemid 36176323)
29. Groll, M.; Huber, R.; Potts, B.C.M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128, 5136-5141.
30. Vinitsky, A.; Michaud, C.; Powers, J.C.; Orlowski, M. Inhibition of the chymotrypsin-Like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992, 31, 9421-9428.
31. Momose, I.; Umezawa, Y.; Hirosawa, S.; Iinuma, H.; Ikeda, D. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg. Med. Chem. Lett. 2005, 15, 1867-1871. (Pubitemid 40380749)
32. Loidl, G.; Groll, M.; Musiol, H.J.; Ditzel, L.; Huber, R.; Moroder, L. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem. Biol. 1999, 6, 197-204. (Pubitemid 29368408)
33. Ma, Y.; Chen, B.; Liu, D.; Yang, Y.; Xiong, Z.; Zeng, J.; Dong, Y. MG132 treatment attenuates cardiac remodeling and dysfunction followingaortic banding in rats via the NF-κB/TGFβ1 pathway. Biochem. Pharmacol. 2011, 81, 1228-1236.
34. Donkor, I.O. A survey of calpain inhibitors. Curr. Med. Chem. 2000, 7, 1171-1188.
35. Tsubuki, S.; Saito, Y.; Tomioka, M.; Ito, H.; Kawashima, S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem. 1996, 119, 572-576. (Pubitemid 26100945)
36. Zhang, X.C.; Kumar, S.; Chen, J.H.; Teplyakov, A.V. Covalent attachment of shape-restricted DNA molecules on amine-functionalized Si(III) surface. Surface Sci. 2009, 603, 2445-2457.
37. Zhu, Y.Q.; Pei, J.F.; Liu, Z.M.; Lai, L.H.; Cui, J.R.; Li, R.T. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods. Bioorg. Med. Chem. 2006, 14, 1483-1496.
38. Liu, J.; Zhang, H.; Xiao, Z.; Wang, F.; Wang, X.; Wang, Y. Combined 3D-QSAR, molecular focking and molecular fynamics dtudy on ferivatives of peptide epoxyketone and tyropeptin-boronic acid as inhibitors against the β5 subunit of Human 20S proteasome. Int. J. Mol. Sci. 2011, 12, 1807-1835.
39. Mckennon, M.J.; Meyers, A.I.; Drauz, K.; Schwarm, M. A Convenient reduction of amino-acids and their derivatives. J. Org. Chem. 1993, 58, 3568-3571.
40. Drag, M.; Latajka, R.; Gumienna-Kontecka, E.; Kozlowski, H.; Kafarski, P. Stereoselective synthesis, solution structure and metal complexes of (1S,2S)-2-amino-1-hydroxyalkylphosphonic acids. Tetrahedron Asymmetry 2003, 14, 1837-1845. (Pubitemid 36776477)
41. Fu, Y.Q.; Xu, B.; Zou, X.M.; Ma, C.; Yang, X.M.; Mou, K.; Fu, G.; Lu, Y.; Xu, P. Design and synthesis of a novel class of furan-based molecules as potential 20S proteasome inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1102-1106. (Pubitemid 46178542)
42. Zhu, Y.Q.; Zhao, X.; Zhu, X.R.; Wu, G.; Li, Y.J.; Ma, Y.H.; Yuan, Y.X.; Yang, J.; Hu, Y.; Ai, L.; Gao, Q.Z. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, Part I: Comprehensive understanding of the SAR of α-amino acid boronates. J. Med. Chem. 2009, 52, 4192-4199.
43. Rydzewski, R.M.; Burrill, L.; Mendonca, R.; Palmer, J.T.; Rice, M.; Tahilramani, R.; Bass, K.E.; Leung, L.; Gjerstad, E.; Janc, J.W.; Pan, L. Optimization of subsite binding to the 5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1, 3, 4-oxadiazoles: Syntheses and cellular properties of potent, selective proteasome inhibitors. J. Med. Chem. 2006, 49, 2953-296